Clinical Effectiveness of Conventional Versus Mirasol-treated
Apheresis Platelets in Patients with Hypoproliferative
The purpose of this study is to learn about the safety and effectiveness of Mirasol Pathogen Reduction Technology System for Platelets. We are hoping to find out if the platelets treated with Mirasol PRT system works the same at preventing and controlling bleeding than platelets as the standard platelet transfusion.
- Greater than 22lbs in weight
- Diagnosis of a hematologic malignancy with hypoproliferative thrombocytopenia
- No treatment with pathogen-reduced blood products in the past 6 months
12 - 120
Healthy Volunteers Needed
Duration of Participation
up to 81 days.
Knight Cancer Intake Center: (503)494-7999
Clinical Trials Information Line: (503)494-1080 or email@example.com
Terumo BCT Biotechnologies